APO Research
Talk to an analyst

APO RESEARCH · REPORT

Oral Factor Xa Inhibitors

Compare research editions
View pricing & licenses

Selected research

Industry Research

Oral Factor Xa Inhibitors Industry Research Report 2026

28 December 2025134 pages

Choose your research edition.

Industry ResearchOral Factor Xa Inhibitors Industry Research Report 2026134 pages · $2,950 USDIndustry Growth & TrendsGlobal Oral Factor Xa Inhibitors Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Oral Factor Xa Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Oral Factor Xa Inhibitors Market Outlook and Growth Opportunities 2026203 pages · $4,250 USDMarket Analysis & ForecastGlobal Oral Factor Xa Inhibitors Market Analysis and Forecast 2026-2032200 pages · $4,950 USD

Market perspective

The global Oral Factor Xa Inhibitors market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Oral Factor Xa Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Oral Factor Xa Inhibitors is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Oral Factor Xa Inhibitors is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Oral Factor Xa Inhibitors include Accord Healthcare, Apotex, Bayer, Bristol Myers Squibb, Daiichi Sankyo, Janssen Pharmaceuticals, Lupin, Mylan and Pfizer, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Oral Factor Xa Inhibitors market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Oral Factor Xa Inhibitors Market by Company

Accord Healthcare

Apotex

Bayer

Bristol Myers Squibb

Daiichi Sankyo

Janssen Pharmaceuticals

Lupin

Mylan

Pfizer

Zydus

HEC Pharma

Hansoh Pharma

Huahai Pharmaceutical

Shanghai Huilun Pharmaceutical

Qilu Pharmaceutical

Cspc Ouyi Pharmaceutical

Yangtze River Pharmaceutical

Zhejiang Hisun Pharmaceutical

Chia Tai Tianqing Pharmaceutical

Oral Factor Xa Inhibitors Segment by Type

Edoxaban

Rivaroxaban

Apixaban

Oral Factor Xa Inhibitors Segment by Application

Pulmonary Embolism

Deep Vein Thrombosis

Atrial Fibrillation

Other

Oral Factor Xa Inhibitors Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oral Factor Xa Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Oral Factor Xa Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oral Factor Xa Inhibitors.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Oral Factor Xa Inhibitors manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Oral Factor Xa Inhibitors by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Oral Factor Xa Inhibitors in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Oral Factor Xa Inhibitors Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Oral Factor Xa Inhibitors Sales (K Units) of Manufacturers (2021-2026) Table 7. Global Oral Factor Xa Inhibitors Sales Market Share by Manufacturers (2021-2026) Table 8. Global Oral Factor Xa Inhibitors Revenue of Manufacturers (2021-2026) Table 9. Global Oral Factor Xa Inhibitors Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Oral Factor Xa Inhibitors Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Oral Factor Xa Inhibitors Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Oral Factor Xa Inhibitors, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Oral Factor Xa Inhibitors, Product Type & Application Table 14. Global Oral Factor Xa Inhibitors Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Oral Factor Xa Inhibitors by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Accord Healthcare Company Information Table 19. Accord Healthcare Business Overview Table 20. Accord Healthcare Oral Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Accord Healthcare Oral Factor Xa Inhibitors Product Portfolio Table 22. Accord Healthcare Recent Developments Table 23. Apotex Company Information Table 24. Apotex Business Overview Table 25. Apotex Oral Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Apotex Oral Factor Xa Inhibitors Product Portfolio Table 27. Apotex Recent Developments Table 28. Bayer Company Information Table 29. Bayer Business Overview Table 30. Bayer Oral Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Bayer Oral Factor Xa Inhibitors Product Portfolio Table 32. Bayer Recent Developments Table 33. Bristol Myers Squibb Company Information Table 34. Bristol Myers Squibb Business Overview Table 35. Bristol Myers Squibb Oral Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Bristol Myers Squibb Oral Factor Xa Inhibitors Product Portfolio Table 37. Bristol Myers Squibb Recent Developments Table 38. Daiichi Sankyo Company Information Table 39. Daiichi Sankyo Business Overview Table 40. Daiichi Sankyo Oral Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Daiichi Sankyo Oral Factor Xa Inhibitors Product Portfolio Table 42. Daiichi Sankyo Recent Developments Table 43. Janssen Pharmaceuticals Company Information Table 44. Janssen Pharmaceuticals Business Overview Table 45. Janssen Pharmaceuticals Oral Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Janssen Pharmaceuticals Oral Factor Xa Inhibitors Product Portfolio Table 47. Janssen Pharmaceuticals Recent Developments Table 48. Lupin Company Information Table 49. Lupin Business Overview Table 50. Lupin Oral Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Lupin Oral Factor Xa Inhibitors Product Portfolio Table 52. Lupin Recent Developments Table 53. Mylan Company Information Table 54. Mylan Business Overview Table 55. Mylan Oral Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. Mylan Oral Factor Xa Inhibitors Product Portfolio Table 57. Mylan Recent Developments Table 58. Pfizer Company Information Table 59. Pfizer Business Overview Table 60. Pfizer Oral Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Pfizer Oral Factor Xa Inhibitors Product Portfolio Table 62. Pfizer Recent Developments Table 63. Zydus Company Information Table 64. Zydus Business Overview Table 65. Zydus Oral Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Zydus Oral Factor Xa Inhibitors Product Portfolio Table 67. Zydus Recent Developments Table 68. HEC Pharma Company Information Table 69. HEC Pharma Business Overview Table 70. HEC Pharma Oral Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. HEC Pharma Oral Factor Xa Inhibitors Product Portfolio Table 72. HEC Pharma Recent Developments Table 73. Hansoh Pharma Company Information Table 74. Hansoh Pharma Business Overview Table 75. Hansoh Pharma Oral Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Hansoh Pharma Oral Factor Xa Inhibitors Product Portfolio Table 77. Hansoh Pharma Recent Developments Table 78. Huahai Pharmaceutical Company Information Table 79. Huahai Pharmaceutical Business Overview Table 80. Huahai Pharmaceutical Oral Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Huahai Pharmaceutical Oral Factor Xa Inhibitors Product Portfolio Table 82. Huahai Pharmaceutical Recent Developments Table 83. Shanghai Huilun Pharmaceutical Company Information Table 84. Shanghai Huilun Pharmaceutical Business Overview Table 85. Shanghai Huilun Pharmaceutical Oral Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Shanghai Huilun Pharmaceutical Oral Factor Xa Inhibitors Product Portfolio Table 87. Shanghai Huilun Pharmaceutical Recent Developments Table 88. Qilu Pharmaceutical Company Information Table 89. Qilu Pharmaceutical Business Overview Table 90. Qilu Pharmaceutical Oral Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Qilu Pharmaceutical Oral Factor Xa Inhibitors Product Portfolio Table 92. Qilu Pharmaceutical Recent Developments Table 93. Cspc Ouyi Pharmaceutical Company Information Table 94. Cspc Ouyi Pharmaceutical Business Overview Table 95. Cspc Ouyi Pharmaceutical Oral Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Cspc Ouyi Pharmaceutical Oral Factor Xa Inhibitors Product Portfolio Table 97. Cspc Ouyi Pharmaceutical Recent Developments Table 98. Yangtze River Pharmaceutical Company Information Table 99. Yangtze River Pharmaceutical Business Overview Table 100. Yangtze River Pharmaceutical Oral Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Yangtze River Pharmaceutical Oral Factor Xa Inhibitors Product Portfolio Table 102. Yangtze River Pharmaceutical Recent Developments Table 103. Zhejiang Hisun Pharmaceutical Company Information Table 104. Zhejiang Hisun Pharmaceutical Business Overview Table 105. Zhejiang Hisun Pharmaceutical Oral Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Zhejiang Hisun Pharmaceutical Oral Factor Xa Inhibitors Product Portfolio Table 107. Zhejiang Hisun Pharmaceutical Recent Developments Table 108. Chia Tai Tianqing Pharmaceutical Company Information Table 109. Chia Tai Tianqing Pharmaceutical Business Overview Table 110. Chia Tai Tianqing Pharmaceutical Oral Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Chia Tai Tianqing Pharmaceutical Oral Factor Xa Inhibitors Product Portfolio Table 112. Chia Tai Tianqing Pharmaceutical Recent Developments Table 113. Global Oral Factor Xa Inhibitors Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 114. Global Oral Factor Xa Inhibitors Sales by Region (2021-2026) & (K Units) Table 115. Global Oral Factor Xa Inhibitors Sales Market Share by Region (2021-2026) Table 116. Global Oral Factor Xa Inhibitors Sales by Region (2027-2032) & (K Units) Table 117. Global Oral Factor Xa Inhibitors Sales Market Share by Region (2027-2032) Table 118. Global Oral Factor Xa Inhibitors Revenue by Region (2021-2026) & (US$ Million) Table 119. Global Oral Factor Xa Inhibitors Revenue Market Share by Region (2021-2026) Table 120. Global Oral Factor Xa Inhibitors Revenue by Region (2027-2032) & (US$ Million) Table 121. Global Oral Factor Xa Inhibitors Revenue Market Share by Region (2027-2032) Table 122. North America Oral Factor Xa Inhibitors Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 123. North America Oral Factor Xa Inhibitors Sales by Country (2021-2026) & (K Units) Table 124. North America Oral Factor Xa Inhibitors Sales by Country (2027-2032) & (K Units) Table 125. North America Oral Factor Xa Inhibitors Revenue by Country (2021-2026) & (US$ Million) Table 126. North America Oral Factor Xa Inhibitors Revenue by Country (2027-2032) & (US$ Million) Table 127. Europe Oral Factor Xa Inhibitors Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 128. Europe Oral Factor Xa Inhibitors Sales by Country (2021-2026) & (K Units) Table 129. Europe Oral Factor Xa Inhibitors Sales by Country (2027-2032) & (K Units) Table 130. Europe Oral Factor Xa Inhibitors Revenue by Country (2021-2026) & (US$ Million) Table 131. Europe Oral Factor Xa Inhibitors Revenue by Country (2027-2032) & (US$ Million) Table 132. Asia Pacific Oral Factor Xa Inhibitors Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 133. Asia Pacific Oral Factor Xa Inhibitors Sales by Country (2021-2026) & (K Units) Table 134. Asia Pacific Oral Factor Xa Inhibitors Sales by Country (2027-2032) & (K Units) Table 135. Asia Pacific Oral Factor Xa Inhibitors Revenue by Country (2021-2026) & (US$ Million) Table 136. Asia Pacific Oral Factor Xa Inhibitors Revenue by Country (2027-2032) & (US$ Million) Table 137. South America Oral Factor Xa Inhibitors Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 138. South America Oral Factor Xa Inhibitors Sales by Country (2021-2026) & (K Units) Table 139. South America Oral Factor Xa Inhibitors Sales by Country (2027-2032) & (K Units) Table 140. South America Oral Factor Xa Inhibitors Revenue by Country (2021-2026) & (US$ Million) Table 141. South America Oral Factor Xa Inhibitors Revenue by Country (2027-2032) & (US$ Million) Table 142. Middle East and Africa Oral Factor Xa Inhibitors Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 143. Middle East and Africa Oral Factor Xa Inhibitors Sales by Country (2021-2026) & (K Units) Table 144. Middle East and Africa Oral Factor Xa Inhibitors Sales by Country (2027-2032) & (K Units) Table 145. Middle East and Africa Oral Factor Xa Inhibitors Revenue by Country (2021-2026) & (US$ Million) Table 146. Middle East and Africa Oral Factor Xa Inhibitors Revenue by Country (2027-2032) & (US$ Million) Table 147. Global Oral Factor Xa Inhibitors Sales by Type (2021-2026) & (K Units) Table 148. Global Oral Factor Xa Inhibitors Sales by Type (2027-2032) & (K Units) Table 149. Global Oral Factor Xa Inhibitors Sales Market Share by Type (2021-2026) Table 150. Global Oral Factor Xa Inhibitors Sales Market Share by Type (2027-2032) Table 151. Global Oral Factor Xa Inhibitors Revenue by Type (2021-2026) & (US$ Million) Table 152. Global Oral Factor Xa Inhibitors Revenue by Type (2027-2032) & (US$ Million) Table 153. Global Oral Factor Xa Inhibitors Revenue Market Share by Type (2021-2026) Table 154. Global Oral Factor Xa Inhibitors Revenue Market Share by Type (2027-2032) Table 155. Global Oral Factor Xa Inhibitors Price by Type (2021-2026) & (US$/Unit) Table 156. Global Oral Factor Xa Inhibitors Price by Type (2027-2032) & (US$/Unit) Table 157. Global Oral Factor Xa Inhibitors Sales by Application (2021-2026) & (K Units) Table 158. Global Oral Factor Xa Inhibitors Sales by Application (2027-2032) & (K Units) Table 159. Global Oral Factor Xa Inhibitors Sales Market Share by Application (2021-2026) Table 160. Global Oral Factor Xa Inhibitors Sales Market Share by Application (2027-2032) Table 161. Global Oral Factor Xa Inhibitors Revenue by Application (2021-2026) & (US$ Million) Table 162. Global Oral Factor Xa Inhibitors Revenue by Application (2027-2032) & (US$ Million) Table 163. Global Oral Factor Xa Inhibitors Revenue Market Share by Application (2021-2026) Table 164. Global Oral Factor Xa Inhibitors Revenue Market Share by Application (2027-2032) Table 165. Global Oral Factor Xa Inhibitors Price by Application (2021-2026) & (US$/Unit) Table 166. Global Oral Factor Xa Inhibitors Price by Application (2027-2032) & (US$/Unit) Table 167. Key Raw Materials Table 168. Raw Materials Key Suppliers Table 169. Oral Factor Xa Inhibitors Distributors List Table 170. Oral Factor Xa Inhibitors Customers List Table 171. Oral Factor Xa Inhibitors Industry Trends Table 172. Oral Factor Xa Inhibitors Industry Drivers Table 173. Oral Factor Xa Inhibitors Industry Restraints Table 174. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Oral Factor Xa Inhibitors Product Image Figure 5. Global Oral Factor Xa Inhibitors Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Oral Factor Xa Inhibitors Market Size (2021-2032) & (US$ Million) Figure 7. Global Oral Factor Xa Inhibitors Sales (2021-2032) & (K Units) Figure 8. Global Oral Factor Xa Inhibitors Average Price (US$/Unit) & (2021-2032) Figure 9. Edoxaban Product Image Figure 10. Rivaroxaban Product Image Figure 11. Apixaban Product Image Figure 12. Pulmonary Embolism Product Image Figure 13. Deep Vein Thrombosis Product Image Figure 14. Atrial Fibrillation Product Image Figure 15. Other Product Image Figure 16. Global Oral Factor Xa Inhibitors Revenue Share by Manufacturers in 2025 Figure 17. Global Manufacturers of Oral Factor Xa Inhibitors, Manufacturing Sites & Headquarters Figure 18. Global Top 5 and 10 Oral Factor Xa Inhibitors Players Market Share by Revenue in 2025 Figure 19. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 20. Global Oral Factor Xa Inhibitors Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 21. Global Oral Factor Xa Inhibitors Sales by Region in 2025 Figure 22. Global Oral Factor Xa Inhibitors Revenue by Region in 2025 Figure 23. North America Oral Factor Xa Inhibitors Market Size by Country in 2025 Figure 24. North America Oral Factor Xa Inhibitors Sales Market Share by Country (2021-2032) Figure 25. North America Oral Factor Xa Inhibitors Revenue Market Share by Country (2021-2032) Figure 26. United States Oral Factor Xa Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Canada Oral Factor Xa Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 28. Mexico Oral Factor Xa Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 29. Europe Oral Factor Xa Inhibitors Market Size by Country in 2025 Figure 30. Europe Oral Factor Xa Inhibitors Sales Market Share by Country (2021-2032) Figure 31. Europe Oral Factor Xa Inhibitors Revenue Market Share by Country (2021-2032) Figure 32. Germany Oral Factor Xa Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. France Oral Factor Xa Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. U.K. Oral Factor Xa Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Italy Oral Factor Xa Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Russia Oral Factor Xa Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Spain Oral Factor Xa Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Netherlands Oral Factor Xa Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Switzerland Oral Factor Xa Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Sweden Oral Factor Xa Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Poland Oral Factor Xa Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Asia Pacific Oral Factor Xa Inhibitors Market Size by Country in 2025 Figure 43. Asia Pacific Oral Factor Xa Inhibitors Sales Market Share by Country (2021-2032) Figure 44. Asia Pacific Oral Factor Xa Inhibitors Revenue Market Share by Country (2021-2032) Figure 45. China Oral Factor Xa Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. Japan Oral Factor Xa Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. South Korea Oral Factor Xa Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. India Oral Factor Xa Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Australia Oral Factor Xa Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Taiwan Oral Factor Xa Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Southeast Asia Oral Factor Xa Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Southeast Asia Oral Factor Xa Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. South America Oral Factor Xa Inhibitors Market Size by Country in 2025 Figure 54. South America Oral Factor Xa Inhibitors Sales Market Share by Country (2021-2032) Figure 55. South America Oral Factor Xa Inhibitors Revenue Market Share by Country (2021-2032) Figure 56. Brazil Oral Factor Xa Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Argentina Oral Factor Xa Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. Chile Oral Factor Xa Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. Middle East and Africa Oral Factor Xa Inhibitors Market Size by Country in 2025 Figure 60. Middle East and Africa Oral Factor Xa Inhibitors Sales Market Share by Country (2021-2032) Figure 61. Middle East and Africa Oral Factor Xa Inhibitors Revenue Market Share by Country (2021-2032) Figure 62. Egypt Oral Factor Xa Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. South Africa Oral Factor Xa Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. Israel Oral Factor Xa Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. Türkiye Oral Factor Xa Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. GCC Countries Oral Factor Xa Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 67. Global Oral Factor Xa Inhibitors Sales Market Share by Type (2021-2032) Figure 68. Global Oral Factor Xa Inhibitors Revenue Market Share by Type (2021-2032) Figure 69. Global Oral Factor Xa Inhibitors Price (US$/Unit) by Type (2021-2032) Figure 70. Global Oral Factor Xa Inhibitors Sales Market Share by Application (2021-2032) Figure 71. Global Oral Factor Xa Inhibitors Revenue Market Share by Application (2021-2032) Figure 72. Global Oral Factor Xa Inhibitors Price (US$/Unit) by Application (2021-2032) Figure 73. Oral Factor Xa Inhibitors Value Chain Figure 74. Oral Factor Xa Inhibitors Production Mode & Process Figure 75. Direct Comparison with Distribution Share Figure 76. Distributors Profiles Figure 77. Oral Factor Xa Inhibitors Industry Opportunities and Challenges

Scope & coverage.

Types
  • Edoxaban
  • Rivaroxaban
  • Apixaban
Applications
  • Pulmonary Embolism
  • Deep Vein Thrombosis
  • Atrial Fibrillation
  • Other
Companies covered
  • Accord Healthcare
  • Apotex
  • Bayer
  • Bristol Myers Squibb
  • Daiichi Sankyo
  • Janssen Pharmaceuticals
  • Lupin
  • Mylan
  • Pfizer
  • Zydus
  • HEC Pharma
  • Hansoh Pharma
  • Huahai Pharmaceutical
  • Shanghai Huilun Pharmaceutical
  • Qilu Pharmaceutical
  • Cspc Ouyi Pharmaceutical
  • Yangtze River Pharmaceutical
  • Zhejiang Hisun Pharmaceutical
  • Chia Tai Tianqing Pharmaceutical

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Oral Factor Xa Inhibitors Market Size (2021-2032)
  4. 2.2.2 Global Oral Factor Xa Inhibitors Sales (2021-2032)
  5. 2.2.3 Global Oral Factor Xa Inhibitors Market Average Price (2021-2032)
  6. 2.3 Oral Factor Xa Inhibitors by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Edoxaban
  9. 2.3.3 Rivaroxaban
  10. 2.3.4 Apixaban
  11. 2.4 Oral Factor Xa Inhibitors by Application
  12. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  13. 2.4.2 Pulmonary Embolism
  14. 2.4.3 Deep Vein Thrombosis
  15. 2.4.4 Atrial Fibrillation
  16. 2.4.5 Other
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Oral Factor Xa Inhibitors Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Oral Factor Xa Inhibitors Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global Oral Factor Xa Inhibitors Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Oral Factor Xa Inhibitors Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Oral Factor Xa Inhibitors Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Oral Factor Xa Inhibitors, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Oral Factor Xa Inhibitors, Product Type & Application
  8. 3.8 Global Manufacturers of Oral Factor Xa Inhibitors, Established Date
  9. 3.9 Global Oral Factor Xa Inhibitors Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Accord Healthcare
  2. 4.1.1 Accord Healthcare Company Information
  3. 4.1.2 Accord Healthcare Business Overview
  4. 4.1.3 Accord Healthcare Oral Factor Xa Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Accord Healthcare Oral Factor Xa Inhibitors Product Portfolio
  6. 4.1.5 Accord Healthcare Recent Developments
  7. 4.2 Apotex
  8. 4.2.1 Apotex Company Information
  9. 4.2.2 Apotex Business Overview
  10. 4.2.3 Apotex Oral Factor Xa Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Apotex Oral Factor Xa Inhibitors Product Portfolio
  12. 4.2.5 Apotex Recent Developments
  13. 4.3 Bayer
  14. 4.3.1 Bayer Company Information
  15. 4.3.2 Bayer Business Overview
  16. 4.3.3 Bayer Oral Factor Xa Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Bayer Oral Factor Xa Inhibitors Product Portfolio
  18. 4.3.5 Bayer Recent Developments
  19. 4.4 Bristol Myers Squibb
  20. 4.4.1 Bristol Myers Squibb Company Information
  21. 4.4.2 Bristol Myers Squibb Business Overview
  22. 4.4.3 Bristol Myers Squibb Oral Factor Xa Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Bristol Myers Squibb Oral Factor Xa Inhibitors Product Portfolio
  24. 4.4.5 Bristol Myers Squibb Recent Developments
  25. 4.5 Daiichi Sankyo
  26. 4.5.1 Daiichi Sankyo Company Information
  27. 4.5.2 Daiichi Sankyo Business Overview
  28. 4.5.3 Daiichi Sankyo Oral Factor Xa Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Daiichi Sankyo Oral Factor Xa Inhibitors Product Portfolio
  30. 4.5.5 Daiichi Sankyo Recent Developments
  31. 4.6 Janssen Pharmaceuticals
  32. 4.6.1 Janssen Pharmaceuticals Company Information
  33. 4.6.2 Janssen Pharmaceuticals Business Overview
  34. 4.6.3 Janssen Pharmaceuticals Oral Factor Xa Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Janssen Pharmaceuticals Oral Factor Xa Inhibitors Product Portfolio
  36. 4.6.5 Janssen Pharmaceuticals Recent Developments
  37. 4.7 Lupin
  38. 4.7.1 Lupin Company Information
  39. 4.7.2 Lupin Business Overview
  40. 4.7.3 Lupin Oral Factor Xa Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Lupin Oral Factor Xa Inhibitors Product Portfolio
  42. 4.7.5 Lupin Recent Developments
  43. 4.8 Mylan
  44. 4.8.1 Mylan Company Information
  45. 4.8.2 Mylan Business Overview
  46. 4.8.3 Mylan Oral Factor Xa Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Mylan Oral Factor Xa Inhibitors Product Portfolio
  48. 4.8.5 Mylan Recent Developments
  49. 4.9 Pfizer
  50. 4.9.1 Pfizer Company Information
  51. 4.9.2 Pfizer Business Overview
  52. 4.9.3 Pfizer Oral Factor Xa Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Pfizer Oral Factor Xa Inhibitors Product Portfolio
  54. 4.9.5 Pfizer Recent Developments
  55. 4.10 Zydus
  56. 4.10.1 Zydus Company Information
  57. 4.10.2 Zydus Business Overview
  58. 4.10.3 Zydus Oral Factor Xa Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Zydus Oral Factor Xa Inhibitors Product Portfolio
  60. 4.10.5 Zydus Recent Developments
  61. 4.11 HEC Pharma
  62. 4.11.1 HEC Pharma Company Information
  63. 4.11.2 HEC Pharma Business Overview
  64. 4.11.3 HEC Pharma Oral Factor Xa Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 HEC Pharma Oral Factor Xa Inhibitors Product Portfolio
  66. 4.11.5 HEC Pharma Recent Developments
  67. 4.12 Hansoh Pharma
  68. 4.12.1 Hansoh Pharma Company Information
  69. 4.12.2 Hansoh Pharma Business Overview
  70. 4.12.3 Hansoh Pharma Oral Factor Xa Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Hansoh Pharma Oral Factor Xa Inhibitors Product Portfolio
  72. 4.12.5 Hansoh Pharma Recent Developments
  73. 4.13 Huahai Pharmaceutical
  74. 4.13.1 Huahai Pharmaceutical Company Information
  75. 4.13.2 Huahai Pharmaceutical Business Overview
  76. 4.13.3 Huahai Pharmaceutical Oral Factor Xa Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Huahai Pharmaceutical Oral Factor Xa Inhibitors Product Portfolio
  78. 4.13.5 Huahai Pharmaceutical Recent Developments
  79. 4.14 Shanghai Huilun Pharmaceutical
  80. 4.14.1 Shanghai Huilun Pharmaceutical Company Information
  81. 4.14.2 Shanghai Huilun Pharmaceutical Business Overview
  82. 4.14.3 Shanghai Huilun Pharmaceutical Oral Factor Xa Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Shanghai Huilun Pharmaceutical Oral Factor Xa Inhibitors Product Portfolio
  84. 4.14.5 Shanghai Huilun Pharmaceutical Recent Developments
  85. 4.15 Qilu Pharmaceutical
  86. 4.15.1 Qilu Pharmaceutical Company Information
  87. 4.15.2 Qilu Pharmaceutical Business Overview
  88. 4.15.3 Qilu Pharmaceutical Oral Factor Xa Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Qilu Pharmaceutical Oral Factor Xa Inhibitors Product Portfolio
  90. 4.15.5 Qilu Pharmaceutical Recent Developments
  91. 4.16 Cspc Ouyi Pharmaceutical
  92. 4.16.1 Cspc Ouyi Pharmaceutical Company Information
  93. 4.16.2 Cspc Ouyi Pharmaceutical Business Overview
  94. 4.16.3 Cspc Ouyi Pharmaceutical Oral Factor Xa Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 Cspc Ouyi Pharmaceutical Oral Factor Xa Inhibitors Product Portfolio
  96. 4.16.5 Cspc Ouyi Pharmaceutical Recent Developments
  97. 4.17 Yangtze River Pharmaceutical
  98. 4.17.1 Yangtze River Pharmaceutical Company Information
  99. 4.17.2 Yangtze River Pharmaceutical Business Overview
  100. 4.17.3 Yangtze River Pharmaceutical Oral Factor Xa Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  101. 4.17.4 Yangtze River Pharmaceutical Oral Factor Xa Inhibitors Product Portfolio
  102. 4.17.5 Yangtze River Pharmaceutical Recent Developments
  103. 4.18 Zhejiang Hisun Pharmaceutical
  104. 4.18.1 Zhejiang Hisun Pharmaceutical Company Information
  105. 4.18.2 Zhejiang Hisun Pharmaceutical Business Overview
  106. 4.18.3 Zhejiang Hisun Pharmaceutical Oral Factor Xa Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  107. 4.18.4 Zhejiang Hisun Pharmaceutical Oral Factor Xa Inhibitors Product Portfolio
  108. 4.18.5 Zhejiang Hisun Pharmaceutical Recent Developments
  109. 4.19 Chia Tai Tianqing Pharmaceutical
  110. 4.19.1 Chia Tai Tianqing Pharmaceutical Company Information
  111. 4.19.2 Chia Tai Tianqing Pharmaceutical Business Overview
  112. 4.19.3 Chia Tai Tianqing Pharmaceutical Oral Factor Xa Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  113. 4.19.4 Chia Tai Tianqing Pharmaceutical Oral Factor Xa Inhibitors Product Portfolio
  114. 4.19.5 Chia Tai Tianqing Pharmaceutical Recent Developments
5 Global Oral Factor Xa Inhibitors Market Scenario by Region
  1. 5.1 Global Oral Factor Xa Inhibitors Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Oral Factor Xa Inhibitors Sales by Region: 2021-2032
  3. 5.2.1 Global Oral Factor Xa Inhibitors Sales by Region: 2021-2026
  4. 5.2.2 Global Oral Factor Xa Inhibitors Sales by Region: 2027-2032
  5. 5.3 Global Oral Factor Xa Inhibitors Revenue by Region: 2021-2032
  6. 5.3.1 Global Oral Factor Xa Inhibitors Revenue by Region: 2021-2026
  7. 5.3.2 Global Oral Factor Xa Inhibitors Revenue by Region: 2027-2032
  8. 5.4 North America Oral Factor Xa Inhibitors Market Facts & Figures by Country
  9. 5.4.1 North America Oral Factor Xa Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Oral Factor Xa Inhibitors Sales by Country (2021-2032)
  11. 5.4.3 North America Oral Factor Xa Inhibitors Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Oral Factor Xa Inhibitors Market Facts & Figures by Country
  16. 5.5.1 Europe Oral Factor Xa Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Oral Factor Xa Inhibitors Sales by Country (2021-2032)
  18. 5.5.3 Europe Oral Factor Xa Inhibitors Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Oral Factor Xa Inhibitors Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Oral Factor Xa Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Oral Factor Xa Inhibitors Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Oral Factor Xa Inhibitors Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Oral Factor Xa Inhibitors Market Facts & Figures by Country
  41. 5.7.1 South America Oral Factor Xa Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Oral Factor Xa Inhibitors Sales by Country (2021-2032)
  43. 5.7.3 South America Oral Factor Xa Inhibitors Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Oral Factor Xa Inhibitors Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Oral Factor Xa Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Oral Factor Xa Inhibitors Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Oral Factor Xa Inhibitors Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Oral Factor Xa Inhibitors Sales by Type (2021-2032)
  2. 6.1.1 Global Oral Factor Xa Inhibitors Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global Oral Factor Xa Inhibitors Sales Market Share by Type (2021-2032)
  4. 6.2 Global Oral Factor Xa Inhibitors Revenue by Type (2021-2032)
  5. 6.2.1 Global Oral Factor Xa Inhibitors Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Oral Factor Xa Inhibitors Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Oral Factor Xa Inhibitors Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Oral Factor Xa Inhibitors Sales by Application (2021-2032)
  2. 7.1.1 Global Oral Factor Xa Inhibitors Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global Oral Factor Xa Inhibitors Sales Market Share by Application (2021-2032)
  4. 7.2 Global Oral Factor Xa Inhibitors Revenue by Application (2021-2032)
  5. 7.2.1 Global Oral Factor Xa Inhibitors Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Oral Factor Xa Inhibitors Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Oral Factor Xa Inhibitors Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Oral Factor Xa Inhibitors Value Chain Analysis
  2. 8.1.1 Oral Factor Xa Inhibitors Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Oral Factor Xa Inhibitors Production Mode & Process
  5. 8.2 Oral Factor Xa Inhibitors Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Oral Factor Xa Inhibitors Distributors
  8. 8.2.3 Oral Factor Xa Inhibitors Customers
9 Global Oral Factor Xa Inhibitors Analyzing Market Dynamics
  1. 9.1 Oral Factor Xa Inhibitors Industry Trends
  2. 9.2 Oral Factor Xa Inhibitors Industry Drivers
  3. 9.3 Oral Factor Xa Inhibitors Industry Opportunities and Challenges
  4. 9.4 Oral Factor Xa Inhibitors Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst